Earlier this year, an association of private clinics in Brazil began negotiations to purchase 5 million doses of a potential coronavirus vaccine developed by Indian lab Bharat Biotech. The move stirred controversy and criticism among experts— who saw it as a way for rich patients to “cut in line” — but regulators have yet to issue their opinion on the matter. Meanwhile, private companies are scrambling to be ready as soon as they have a green light from authorities. Within this parallel vaccine race, a new, big hitter is looking to join the fray: health tech Dr. Consulta.
...
